Publications
92
Citations
1,323
Est. group size
~1
Recurring co-author estimate
Active years
22
Publishing since 2005
Megan A. Waldrop's work focuses on neuromuscular disorders in children and adults, particularly spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD), including studies of newer gene therapies and exon-skipping drugs. Her publications commonly involve clinical outcomes research, treatment guidelines, and real-world safety/efficacy tracking through patient registries and long-term follow-up studies. This research is aimed at improving diagnosis, treatment timing, and care standards for patients with these genetic muscle-wasting conditions.
Publication output has remained fairly active and somewhat variable over the last decade, rising from single digits in 2017 to peaks of around 12-14 papers per year in 2019-2020 and again in 2024, with a modest recent decline.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD
Journal of Comparative Effectiveness Research · 2026
- Safety and efficacy of intravenous onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy type 1: interim analysis from LT-001, a long-term follow-up study of patients from the START study
EClinicalMedicine · 2026
- Trach and treat: Safety and motor outcomes following onasemnogene abeparvovec in patients with spinal muscular atrophy and tracheostomies in the RESTORE registry
Journal of Neuromuscular Diseases · 2025
- Comparison of Two Questionnaires for Sleep‐Related Symptoms in Pediatric and Adult Patients With Myotonic Dystrophy Type 1
Muscle & Nerve · 2025
- Development of a Clinical Tool to Aid in the Diagnosis of Duchenne Muscular Dystrophy (P7-6.010)
Neurology · 2025
- Spinal Muscular Atrophy Update in Best Practices
Neurology Clinical Practice · 2024
- The Early Care (0–3 Years) In Duchenne Muscular Dystrophy Meeting Report
Journal of Neuromuscular Diseases · 2024
- Clinical decision making around commercial use of gene and genetic therapies for spinal muscular atrophy
Neurotherapeutics · 2024
- Long-Term Follow-Up Cares and Check Initiative: A Program to Advance Long-Term Follow-Up in Newborns Identified with a Disease through Newborn Screening
International Journal of Neonatal Screening · 2024
- 162P Real-world outcomes following onasemnogene abeparvovec in patients with SMA and invasive ventilatory support: findings from the RESTORE Registry
Neuromuscular Disorders · 2024
- P31 Interim analysis of EVOLVE: evaluating Eteplirsen, Golodirsen, or Casimersen treatment in patients <7 years old in routine clinical practice
Neuromuscular Disorders · 2023
- Time is muscle: A recommendation for early treatment for preterm infants with spinal muscular atrophy
Muscle & Nerve · 2021
- Overview of gene therapy in spinal muscular atrophy and Duchenne muscular dystrophy
Pediatric Pulmonology · 2020
- Spinal Muscular Atrophy in the Treatment Era
Neurologic Clinics · 2020
- Overview of Gene Therapy in Spinal Muscular Atrophy and Duchenne Muscular Dystrophy
2020
- Neuromuscular Disorders×29
- Journal of Neuromuscular Diseases×7
- Muscle & Nerve×5
- Genetics in Medicine×3
- Pediatric Neurology×3
- Arthur H.M. Burghes
Medicine · The Ohio State University
- Anton J. Blatnik
Medicine · The Ohio State University
- Richard Shell
Medicine · The Ohio State University
- Matthew E.R. Butchbach
Medicine · The Ohio State University
- Stephen J. Kolb
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile